Drug profile

The FDA adverse-event record for Moraxella Bovis Bacterin

22 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Moraxella Bovis Bacterin. Species, reactions, and outcomes follow.

#1709 of 2,679
by report volume (all drugs)
22
adverse-event reports
31.8%
death-coded share
Cattle
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Moraxella Bovis Bacterin ranks #1671 of 2679 by total reports (22). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1671
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Moraxella Bovis Bacterin has 22 reports now versus 22 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Moraxella Bovis Bacterin changes

Signature read: Moraxella Bovis Bacterin's 31.8% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
7
Deaths Reported
31.8%
Death-coded share of reports

Active Ingredients

Moraxella Bovis Bacterin

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Cattle 22

Most Affected Breeds

Cattle (other) 13
Cattle (unknown) 3
Aberdeen Angus 2
Crossbred Bovine/Cattle 1
Brangus 1
Holstein-Friesian also known as Holstein 1
Mixed (Cattle) 1

Most Reported Reactions

Lack of efficacy - NOS 8
Death 4
Partial lack of efficacy 2
Nasal discharge 2
Sudden death 2
Pneumonia 2
Pink eye 2
Rectal prolapse 2
INEFFECTIVE, PARASITE(S) NOS 1
Keratoconjunctivitis 1
Oral bleeding 1
Respiratory signs 1

Outcome Breakdown

Recovered/Normal
8 (30.8%)
Died
7 (26.9%)
Outcome Unknown
6 (23.1%)
Ongoing
5 (19.2%)

Moraxella Bovis Bacterin: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Moraxella Bovis Bacterin (#1709 of 2,679 by report volume); death-coded 31.8%. PlainBreed drug row · death-coded share stamp 31.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →